<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34831183</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2073-4409</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cells</Title>
          <ISOAbbreviation>Cells</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Metabolic Control of Myeloid Cells in the Tumor Microenvironment.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">2960</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10112960</ELocationID>
        <Abstract>
          <AbstractText>Myeloid cells are a key determinant of tumor progression and patient outcomes in a range of cancers and are therefore being actively pursued as targets of new immunotherapies. The recent use of high-dimensional single-cell approaches, e.g., mass cytometry and single-cell RNA-sequencing (scRNA-seq) has reinforced the predominance of myeloid cells in the tumor microenvironment and uncovered their phenotypic diversity in different cancers. The cancerous metabolic environment has emerged as a critical modulator of myeloid cell functions in anti-tumor immunity versus immune suppression and immune evasion. Here, we discuss mechanisms of immune-metabolic crosstalk in tumorigenesis, with a particular focus on the tumor-associated myeloid cell's metabolic programs. We highlight the impact of several metabolic pathways on the pro-tumoral functions of tumor-associated macrophages and myeloid-derived suppressor cells and discuss the potential myeloid cell metabolic checkpoints for cancer immunotherapy, either as monotherapies or in combination with other immunotherapies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ramel</LastName>
            <ForeName>Eloise</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>ImmunoConcEpT, CNRS, University of Bordeaux, UMR 5164, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lillo</LastName>
            <ForeName>Sebastian</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>ImmunoConcEpT, CNRS, University of Bordeaux, UMR 5164, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Daher</LastName>
            <ForeName>Boutaina</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-8952-3128</Identifier>
            <AffiliationInfo>
              <Affiliation>Institut de Biochimie et Génétique Cellulaires (IBGC), CNRS, University of Bordeaux, UMR 5095, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fioleau</LastName>
            <ForeName>Marina</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>ImmunoConcEpT, CNRS, University of Bordeaux, UMR 5164, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Daubon</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-0319-7617</Identifier>
            <AffiliationInfo>
              <Affiliation>Institut de Biochimie et Génétique Cellulaires (IBGC), CNRS, University of Bordeaux, UMR 5095, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saleh</LastName>
            <ForeName>Maya</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-1538-9146</Identifier>
            <AffiliationInfo>
              <Affiliation>ImmunoConcEpT, CNRS, University of Bordeaux, UMR 5164, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, McGill University, Montreal, QC H3G 0B1, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cells</MedlineTA>
        <NlmUniqueID>101600052</NlmUniqueID>
        <ISSNLinking>2073-4409</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051153" MajorTopicYN="N">Wnt Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">cancer</Keyword>
        <Keyword MajorTopicYN="Y">cellular metabolism</Keyword>
        <Keyword MajorTopicYN="Y">immunometabolism</Keyword>
        <Keyword MajorTopicYN="Y">immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">macrophages</Keyword>
        <Keyword MajorTopicYN="Y">myeloid cells</Keyword>
        <Keyword MajorTopicYN="Y">tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>1</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34831183</ArticleId>
        <ArticleId IdType="pmc">PMC8616208</ArticleId>
        <ArticleId IdType="doi">10.3390/cells10112960</ArticleId>
        <ArticleId IdType="pii">cells10112960</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chakarov S., Lim H.Y., Tan L., Lim S.Y., See P., Lum J., Zhang X.-M., Foo S., Nakamizo S., Duan K., et al.  Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science. 2019;363:eaau0964. doi: 10.1126/science.aau0964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aau0964</ArticleId>
            <ArticleId IdType="pubmed">30872492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassetta L., Pollard J.W. Targeting macrophages: Therapeutic approaches in cancer. Nat. Rev. Drug Discov. 2018;17:887–904. doi: 10.1038/nrd.2018.169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd.2018.169</ArticleId>
            <ArticleId IdType="pubmed">30361552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavin Y., Mortha A., Rahman A., Merad M. Regulation of macrophage development and function in peripheral tissues. Nat. Rev. Immunol. 2015;15:731–744. doi: 10.1038/nri3920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3920</ArticleId>
            <ArticleId IdType="pmc">PMC4706379</ArticleId>
            <ArticleId IdType="pubmed">26603899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Y., Herndon J.M., Sojka D.K., Kim K.W., Knolhoff B.L., Zuo C., Cullinan D.R., Luo J., Bearden A.R., Lavine K.J., et al.  Tissue-resident macrophages in pancreatic ductal Adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity. 2017;47:323–338. doi: 10.1016/j.immuni.2017.07.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2017.07.014</ArticleId>
            <ArticleId IdType="pmc">PMC5578409</ArticleId>
            <ArticleId IdType="pubmed">28813661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma A., Seow J.J.W., Dutertre C.-A., Pai R., Blériot C., Mishra A., Wong R.M.M., Singh G.S.N., Sudhagar S., Khalilnezhad S., et al.  Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell. 2020;183:377–394. doi: 10.1016/j.cell.2020.08.040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.08.040</ArticleId>
            <ArticleId IdType="pubmed">32976798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casanova-Acebes M., Dalla E., Leader A.M., LeBerichel J., Nikolic J., Morales B.M., Brown M., Chang C., Troncoso L., Chen S.T., et al.  Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nat. Cell Biol. 2021;595:578–584. doi: 10.1038/s41586-021-03651-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03651-8</ArticleId>
            <ArticleId IdType="pubmed">34135508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J. Gen. Physiol. 1927;8:519–530. doi: 10.1085/jgp.8.6.519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1085/jgp.8.6.519</ArticleId>
            <ArticleId IdType="pmc">PMC2140820</ArticleId>
            <ArticleId IdType="pubmed">19872213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O′Neill L.A.J., Kishton R.J., Rathmell J. A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 2016;16:553–565. doi: 10.1038/nri.2016.70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2016.70</ArticleId>
            <ArticleId IdType="pmc">PMC5001910</ArticleId>
            <ArticleId IdType="pubmed">27396447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Werno C., Menrad H., Weigert A., Dehne N., Goerdt S., Schledzewski K., Kzhyshkowska J., Brüne B. Knockout of HIF-1 in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis. 2010;31:1863–1872. doi: 10.1093/carcin/bgq088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgq088</ArticleId>
            <ArticleId IdType="pubmed">20427344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imtiyaz H.Z., Williams E.P., Hickey M.M., Patel S.A., Durham A.C., Yuan L.-J., Hammond R., Gimotty P.A., Keith B., Simon M.C. Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Investig. 2010;120:2699–2714. doi: 10.1172/JCI39506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI39506</ArticleId>
            <ArticleId IdType="pmc">PMC2912179</ArticleId>
            <ArticleId IdType="pubmed">20644254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casazza A., Laoui D., Wenes M., Rizzolio S., Bassani N., Mambretti M., Deschoemaeker S., Van Ginderachter J.A., Tamagnone L., Mazzone M. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell. 2013;24:695–709. doi: 10.1016/j.ccr.2013.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.11.007</ArticleId>
            <ArticleId IdType="pubmed">24332039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tannahill G.M., Curtis A.M., Adamik J., Palsson-McDermott E.M., McGettrick A.F., Goel G., Frezza C., Bernard N.J., Kelly B., Foley N.H., et al.  Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature. 2013;496:238–242. doi: 10.1038/nature11986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11986</ArticleId>
            <ArticleId IdType="pmc">PMC4031686</ArticleId>
            <ArticleId IdType="pubmed">23535595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palsson-McDermott E.M., Curtis A.M., Goel G., Lauterbach M.A.R., Sheedy F.J., Gleeson L.E., van den Bosch M.W.M., Quinn S.R., Domingo-Fernandez R., Johnston D.G.W., et al.  Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015;21:347. doi: 10.1016/j.cmet.2015.01.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2015.01.017</ArticleId>
            <ArticleId IdType="pubmed">29510100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jha A.K., Huang S.C.-C., Sergushichev A., Lampropoulou V., Ivanova Y., Loginicheva E., Chmielewski K., Stewart K.M., Ashall J., Everts B., et al.  Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42:419–430. doi: 10.1016/j.immuni.2015.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2015.02.005</ArticleId>
            <ArticleId IdType="pubmed">25786174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander R.K., Liou Y.-H., Knudsen N.H., Starost K.A., Xu C., Hyde A.L., Liu S., Jacobi D., Liao N.-S., Lee C.-H. Bmal1 integrates mitochondrial metabolism and macrophage activation. eLife. 2020;9:54090. doi: 10.7554/eLife.54090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.54090</ArticleId>
            <ArticleId IdType="pmc">PMC7259948</ArticleId>
            <ArticleId IdType="pubmed">32396064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De-Brito N.M., Duncan-Moretti J., Da-Costa H.C., Saldanha-Gama R., Paula-Neto H.A., Dorighello G., Simões R.L., Barja-Fidalgo C. Aerobic glycolysis is a metabolic requirement to maintain the M2-like polarization of tumor-associated macrophages. Biochim. Biophys. Acta BBA Bioenerg. 2020;1867:118604. doi: 10.1016/j.bbamcr.2019.118604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2019.118604</ArticleId>
            <ArticleId IdType="pubmed">31760090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J.-Y., Huang T.-W., Hsieh Y.-T., Wang Y.-F., Yen C.-C., Lee G.-L., Yeh C.-C., Peng Y.-J., Kuo Y.-Y., Wen H.-T., et al.  Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol. Cell. 2020;77:213–227. doi: 10.1016/j.molcel.2019.10.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2019.10.023</ArticleId>
            <ArticleId IdType="pubmed">31735641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.-I., Cheng P., Cho H.-I., Celis E., Quiceno D.G., Padhya T., et al.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010;207:2439–2453. doi: 10.1084/jem.20100587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20100587</ArticleId>
            <ArticleId IdType="pmc">PMC2964584</ArticleId>
            <ArticleId IdType="pubmed">20876310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noman M.Z., Desantis G., Janji B., Hasmim M., Karray S., Dessen P., Bronte V., Chouaib S. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 2014;211:781–790. doi: 10.1084/jem.20131916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20131916</ArticleId>
            <ArticleId IdType="pmc">PMC4010891</ArticleId>
            <ArticleId IdType="pubmed">24778419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxton R.A., Sabatini D.M. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–976. doi: 10.1016/j.cell.2017.02.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.02.004</ArticleId>
            <ArticleId IdType="pmc">PMC5394987</ArticleId>
            <ArticleId IdType="pubmed">28283069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxton R.A., Sabatini D.M. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169:361–371. doi: 10.1016/j.cell.2017.03.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.03.035</ArticleId>
            <ArticleId IdType="pubmed">28388417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linke M., Fritsch S.D., Sukhbaatar N., Hengstschläger M., Weichhart T. mTORC1 and mTORC2 as regulators of cell metabolism in immunity. FEBS Lett. 2017;591:3089–3103. doi: 10.1002/1873-3468.12711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1873-3468.12711</ArticleId>
            <ArticleId IdType="pmc">PMC6322652</ArticleId>
            <ArticleId IdType="pubmed">28600802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welte T., Kim I.S., Tian L., Gao X., Wang H., Li J., Holdman X.B., Herschkowitz J.I., Pond A., Xie G., et al.  Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat. Cell Biol. 2016;18:632–644. doi: 10.1038/ncb3355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3355</ArticleId>
            <ArticleId IdType="pmc">PMC4884142</ArticleId>
            <ArticleId IdType="pubmed">27183469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katholnig K., Schütz B., Fritsch S.D., Schörghofer D., Linke M., Sukhbaatar N., Matschinger J.M., Unterleuthner D., Hirtl M., Lang M., et al.  Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis. JCI Insight. 2019;4:24. doi: 10.1172/jci.insight.124164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.124164</ArticleId>
            <ArticleId IdType="pmc">PMC6824305</ArticleId>
            <ArticleId IdType="pubmed">31619583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding C., Sun X., Wu C., Hu X., Zhang H.-G., Yan J. Tumor microenvironment modulates immunological outcomes of myeloid cells with mTORC1 disruption. J. Immunol. 2019;202:1623–1634. doi: 10.4049/jimmunol.1801112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1801112</ArticleId>
            <ArticleId IdType="pmc">PMC6382613</ArticleId>
            <ArticleId IdType="pubmed">30665937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins S.L., Oh M.-H., Sun I.-H., Chan-Li Y., Zhao L., Powell J.D., Horton M.R. mTORC1 signaling regulates proinflammatory macrophage function and metabolism. J. Immunol. 2021;207:913–922. doi: 10.4049/jimmunol.2100230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.2100230</ArticleId>
            <ArticleId IdType="pubmed">34290107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Covarrubias A.J., Aksoylar H.I., Yu J., Snyder N.W., Worth A.J., Iyer S.S., Wang J., Ben-Sahra I., Byles V., Polynne-Stapornkul T., et al.  Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. Elife. 2016;5:e11612. doi: 10.7554/eLife.11612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.11612</ArticleId>
            <ArticleId IdType="pmc">PMC4769166</ArticleId>
            <ArticleId IdType="pubmed">26894960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linke M., Pham H.T.T., Katholnig K., Schnöller T., Miller A., Demel F., Schütz B., Rosner M., Kovacic B., Sukhbaatar N., et al.  Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat. Immunol. 2017;18:293–302. doi: 10.1038/ni.3655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3655</ArticleId>
            <ArticleId IdType="pmc">PMC5321578</ArticleId>
            <ArticleId IdType="pubmed">28092373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson J.L., Nagele T., Linke M., Demel F., Fritsch S.D., Mayr H.K., Cai Z., Katholnig K., Sun X., Fragner L., et al.  Inverse data-driven modeling and multiomics analysis reveals phgdh as a metabolic checkpoint of macrophage polarization and proliferation. Cell Rep. 2020;30:1542–1552. doi: 10.1016/j.celrep.2020.01.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2020.01.011</ArticleId>
            <ArticleId IdType="pmc">PMC7003064</ArticleId>
            <ArticleId IdType="pubmed">32023468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byles V., Covarrubias A.J., Ben-Sahra I., Lamming D.W., Sabatini D.M., Manning B.D., Horng T. The TSC-mTOR pathway regulates macrophage polarization. Nat. Commun. 2013;4:2834. doi: 10.1038/ncomms3834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms3834</ArticleId>
            <ArticleId IdType="pmc">PMC3876736</ArticleId>
            <ArticleId IdType="pubmed">24280772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corbet C., Feron O. Tumour acidosis: From the passenger to the driver′s seat. Nat. Rev. Cancer. 2017;17:577–593. doi: 10.1038/nrc.2017.77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2017.77</ArticleId>
            <ArticleId IdType="pubmed">28912578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmona-Fontaine C., Deforet M., Akkari L., Thompson C.B., Joyce J.A., Xavier J.B. Metabolic origins of spatial organization in the tumor microenvironment. Proc. Natl. Acad. Sci. USA. 2017;114:2934–2939. doi: 10.1073/pnas.1700600114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1700600114</ArticleId>
            <ArticleId IdType="pmc">PMC5358370</ArticleId>
            <ArticleId IdType="pubmed">28246332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu N., Luo J., Kuang D., Xu S., Duan Y., Xia Y., Wei Z., Xie X., Yin B., Chen F., et al.  Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2α–mediated tumor progression. J. Clin. Investig. 2019;129:631–646. doi: 10.1172/JCI123027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI123027</ArticleId>
            <ArticleId IdType="pmc">PMC6355226</ArticleId>
            <ArticleId IdType="pubmed">30431439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colegio O.R., Chu N.-Q., Szabo A.L., Chu T., Rhebergen A.M., Jairam V., Cyrus N., Brokowski C.E., Eisenbarth S.C., Phillips G.M., et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559–563. doi: 10.1038/nature13490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13490</ArticleId>
            <ArticleId IdType="pmc">PMC4301845</ArticleId>
            <ArticleId IdType="pubmed">25043024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D., Tang Z., Huang H., Zhou G., Cui C., Weng Y., Liu W., Kim S., Lee S., Perez-Neut M., et al.  Metabolic regulation of gene expression by histone lactylation. Nat. Cell Biol. 2019;574:575–580. doi: 10.1038/s41586-019-1678-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1678-1</ArticleId>
            <ArticleId IdType="pmc">PMC6818755</ArticleId>
            <ArticleId IdType="pubmed">31645732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bohn T., Rapp S., Luther N., Klein M., Bruehl T.-J., Kojima N., Lopez P.A., Hahlbrock J., Muth S., Endo S., et al.  Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nat. Immunol. 2018;19:1319–1329. doi: 10.1038/s41590-018-0226-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-018-0226-8</ArticleId>
            <ArticleId IdType="pubmed">30397348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: An immunologic functional perspective. Annu. Rev. Immunol. 2009;27:451–483. doi: 10.1146/annurev.immunol.021908.132532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.021908.132532</ArticleId>
            <ArticleId IdType="pubmed">19105661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sankowski R., Böttcher C., Masuda T., Geirsdottir L., Sindram E., Seredenina T., Muhs A., Scheiwe C., Shah M.J., Heiland D.H., et al.  Mapping microglia states in the human brain through the integration of high-dimensional techniques. Nat. Neurosci. 2019;22:2098–2110. doi: 10.1038/s41593-019-0532-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41593-019-0532-y</ArticleId>
            <ArticleId IdType="pubmed">31740814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z., Xu J., Ma Q., Zhang X., Yang Q., Wang L., Cao Y., Xu Z., Tawfik A., Sun Y., et al.  Glycolysis links reciprocal activation of myeloid cells and endothelial cells in the retinal angiogenic niche. Sci. Transl. Med. 2020;12:eaay1371. doi: 10.1126/scitranslmed.aay1371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aay1371</ArticleId>
            <ArticleId IdType="pmc">PMC7751280</ArticleId>
            <ArticleId IdType="pubmed">32759274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Yu G., Chu H., Wang X., Xiong L., Cai G., Liu R., Gao H., Tao B., Li W., et al.  Macrophage-associated PGK1 phosphorylation promotes aerobic glycolysis and tumorigenesis. Mol. Cell. 2018;71:201–215. doi: 10.1016/j.molcel.2018.06.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2018.06.023</ArticleId>
            <ArticleId IdType="pubmed">30029001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen F., Chen J., Yang L., Liu J., Zhang X., Zhang Y., Tu Q., Yin D., Lin D., Wong P.P., et al.  Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat. Cell Biol. 2019;21:498–510. doi: 10.1038/s41556-019-0299-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-019-0299-0</ArticleId>
            <ArticleId IdType="pubmed">30936474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmieri E.M., Menga A., Martín-Pérez R., Quinto A., Riera-Domingo C., De Tullio G., Hooper D.C., Lamers W.H., Ghesquière B., McVicar D.W., et al.  Pharmacologic or genetic targeting of glutamine synthetase skews macrophages toward an M1-like phenotype and inhibits tumor metastasis. Cell Rep. 2017;20:1654–1666. doi: 10.1016/j.celrep.2017.07.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.07.054</ArticleId>
            <ArticleId IdType="pmc">PMC5575233</ArticleId>
            <ArticleId IdType="pubmed">28813676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menga A., Serra M., Todisco S., Riera-Domingo C., Ammarah U., Ehling M., Palmieri E.M., Di Noia M.A., Gissi R., Favia M., et al.  Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages. EMBO Mol. Med. 2020;12:27. doi: 10.15252/emmm.201911210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201911210</ArticleId>
            <ArticleId IdType="pmc">PMC7539200</ArticleId>
            <ArticleId IdType="pubmed">32885605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P.-T., Wang H., Li X., Chao T., Teav T., Christen S., Di Conza G., Cheng W.-C., Chou C.-H., Vavakova M., et al.  α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat. Immunol. 2017;18:985–994. doi: 10.1038/ni.3796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3796</ArticleId>
            <ArticleId IdType="pubmed">28714978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu W.-C., Sun H.-W., Chen J., Ouyang H.-Y., Yu X.-J., Chen H.-T., Shuang Z.-Y., Shi M., Wang Z., Zheng L. Immunosuppressive immature myeloid cell generation is controlled by glutamine metabolism in human cancer. Cancer Immunol. Res. 2019;7:1605–1618. doi: 10.1158/2326-6066.CIR-18-0902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0902</ArticleId>
            <ArticleId IdType="pubmed">31387898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun H.-W., Wu W.-C., Chen H.-T., Xu Y.-T., Yang Y.-Y., Chen J., Yu X.-J., Wang Z., Shuang Z.-Y., Zheng L. Glutamine deprivation promotes the generation and mobilization of MDSCs by enhancing expression of G-CSF and GM-CSF. Front. Immunol. 2021;11:616367. doi: 10.3389/fimmu.2020.616367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.616367</ArticleId>
            <ArticleId IdType="pmc">PMC7884351</ArticleId>
            <ArticleId IdType="pubmed">33603745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh M.-H., Sun I.-H., Zhao L., Leone R.D., Sun I.M., Xu W., Collins S.L., Tam A.J., Blosser R.L., Patel C.H., et al.  Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J. Clin. Investig. 2020;130:3865–3884. doi: 10.1172/JCI131859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI131859</ArticleId>
            <ArticleId IdType="pmc">PMC7324212</ArticleId>
            <ArticleId IdType="pubmed">32324593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Q., Kuang D.-M., Wu Y., Xiao X., Li X.-F., Li T.-J., Zheng L. Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J. Immunol. 2012;188:1117–1124. doi: 10.4049/jimmunol.1100164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1100164</ArticleId>
            <ArticleId IdType="pubmed">22184722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su S., Zhao J., Xing Y., Zhang X., Liu J., Ouyang Q., Chen J., Su F., Liu Q., Song E. Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages. Cell. 2018;175:442–457.e23. doi: 10.1016/j.cell.2018.09.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.09.007</ArticleId>
            <ArticleId IdType="pubmed">30290143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Opitz C.A., Litzenburger U.M., Sahm F., Ott M., Tritschler I., Trump S., Schumacher T., Jestaedt L., Schrenk D., Weller M., et al.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478:197–203. doi: 10.1038/nature10491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10491</ArticleId>
            <ArticleId IdType="pubmed">21976023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takenaka M.C., Gabriely G., Rothhammer V., Mascanfroni I.D., Wheeler M.A., Chao C.-C., Gutiérrez-Vázquez C., Kenison J., Tjon E.C., Barroso A., et al.  Author correction: Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat. Neurosci. 2019;22:1533. doi: 10.1038/s41593-019-0446-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41593-019-0446-8</ArticleId>
            <ArticleId IdType="pubmed">31197266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campesato L.F., Budhu S., Tchaicha J., Weng C.-H., Gigoux M., Cohen I.J., Redmond D., Mangarin L., Pourpe S., Liu C., et al.  Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat. Commun. 2020;11:4011. doi: 10.1038/s41467-020-17750-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-17750-z</ArticleId>
            <ArticleId IdType="pmc">PMC7419300</ArticleId>
            <ArticleId IdType="pubmed">32782249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmieri E.M., Gonzalez-Cotto M., Baseler W.A., Davies L.C., Ghesquière B., Maio N., Rice C.M., Rouault T.A., Cassel T., Higashi R.M., et al.  Nitric oxide orchestrates metabolic rewiring in M1 macrophages by targeting aconitase 2 and pyruvate dehydrogenase. Nat. Commun. 2020;11:698. doi: 10.1038/s41467-020-14433-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-14433-7</ArticleId>
            <ArticleId IdType="pmc">PMC7000728</ArticleId>
            <ArticleId IdType="pubmed">32019928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brentville V.A., Metheringham R.L., Daniels I., Atabani S., Symonds P., Cook K.W., Vankemmelbeke M., Choudhury R., Vaghela P., Gijon M., et al.  Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses. J. Immunother. Cancer. 2020;8:e000560. doi: 10.1136/jitc-2020-000560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-000560</ArticleId>
            <ArticleId IdType="pmc">PMC7304843</ArticleId>
            <ArticleId IdType="pubmed">32561639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mills C.D., Shearer J., Evans R., Caldwell M.D. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J. Immunol. 1992;149:2709–2714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1401910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., Delgado A., Correa P., Brayer J., Sotomayor E.M., et al.  Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839–5849. doi: 10.1158/0008-5472.CAN-04-0465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-04-0465</ArticleId>
            <ArticleId IdType="pubmed">15313928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia H., Li S., Li X., Wang W., Bian Y., Wei S., Grove S., Wang W., Vatan L., Liu J.R., et al.  Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis. JCI Insight. 2020;5:141115. doi: 10.1172/jci.insight.141115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.141115</ArticleId>
            <ArticleId IdType="pmc">PMC7526547</ArticleId>
            <ArticleId IdType="pubmed">32780724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badeaux M.D., Rolig A.S., Agnello G., Enzler D., Kasiewicz M.J., Priddy L., Wiggins J.F., Muir A., Sullivan M.R., Van Cleef J., et al.  Arginase therapy combines effectively with immune checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth. Cancer Immunol. Res. 2021;9:415–429. doi: 10.1158/2326-6066.CIR-20-0317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-20-0317</ArticleId>
            <ArticleId IdType="pubmed">33500272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava M.K., Sinha P., Clements V.K., Rodriguez P., Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70:68–77. doi: 10.1158/0008-5472.CAN-09-2587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-2587</ArticleId>
            <ArticleId IdType="pmc">PMC2805057</ArticleId>
            <ArticleId IdType="pubmed">20028852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mills E.L., Kelly B., Logan A., Costa A.S., Varma M., Bryant C., Tourlomousis P., Däbritz J.H.M., Gottlieb E., Latorre I., et al.  Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell. 2017;167:457–470. doi: 10.1016/j.cell.2016.08.064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.08.064</ArticleId>
            <ArticleId IdType="pmc">PMC5863951</ArticleId>
            <ArticleId IdType="pubmed">27667687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang S., Ma H.-Y., Zhong Z., Dhar D., Liu X., Xu J., Koyama Y., Nishio T., Karin D., Karin G., et al.  NADPH oxidase 1 in liver macrophages promotes inflammation and tumor development in mice. Gastroenterology. 2019;156:1156–1172. doi: 10.1053/j.gastro.2018.11.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2018.11.019</ArticleId>
            <ArticleId IdType="pmc">PMC6409207</ArticleId>
            <ArticleId IdType="pubmed">30445007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roux C., Jafari S.M., Shinde R., Duncan G., Cescon D.W., Silvester J., Chu M.F., Hodgson K., Berger T., Wakeham A., et al.  Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proc. Natl. Acad. Sci. USA. 2019;116:4326–4335. doi: 10.1073/pnas.1819473116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1819473116</ArticleId>
            <ArticleId IdType="pmc">PMC6410837</ArticleId>
            <ArticleId IdType="pubmed">30770442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76–86. doi: 10.1101/gad.13.1.76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.13.1.76</ArticleId>
            <ArticleId IdType="pmc">PMC316370</ArticleId>
            <ArticleId IdType="pubmed">9887101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu K., Alcivar A.L., Ma J., Foo T.K., Zywea S., Mahdi A., Huo Y., Kensler T., Gatza M., Xia B. NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress–induced DPP3–KEAP1 interaction. Cancer Res. 2017;77:2881–2892. doi: 10.1158/0008-5472.CAN-16-2204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-2204</ArticleId>
            <ArticleId IdType="pmc">PMC5464605</ArticleId>
            <ArticleId IdType="pubmed">28416489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi E.H., Suzuki T., Funayama R., Nagashima T., Hayashi M., Sekine H., Tanaka N., Moriguchi T., Motohashi H., Nakayama K., et al.  Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat. Commun. 2016;7:11624. doi: 10.1038/ncomms11624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms11624</ArticleId>
            <ArticleId IdType="pmc">PMC4879264</ArticleId>
            <ArticleId IdType="pubmed">27211851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye P., Mimura J., Okada T., Sato H., Liu T., Maruyama A., Ohyama C., Itoh K. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol. Cell. Biol. 2014;34:3421–3434. doi: 10.1128/MCB.00221-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.00221-14</ArticleId>
            <ArticleId IdType="pmc">PMC4135628</ArticleId>
            <ArticleId IdType="pubmed">25002527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye P., Mimura J., Okada T., Sato H., Liu T., Maruyama A., Ohyama C., Itoh K. Correction for Ye et al., Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol. Cell. Biol. 2015;35:2366. doi: 10.1128/MCB.00404-15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.00404-15</ArticleId>
            <ArticleId IdType="pmc">PMC4456444</ArticleId>
            <ArticleId IdType="pubmed">26044038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiramoto K., Satoh H., Suzuki T., Moriguchi T., Pi J., Shimosegawa T., Yamamoto M. Myeloid lineage—Specific deletion of antioxidant system enhances tumor metastasis. Cancer Prev. Res. 2014;7:835–844. doi: 10.1158/1940-6207.CAPR-14-0094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1940-6207.CAPR-14-0094</ArticleId>
            <ArticleId IdType="pubmed">24866179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vats D., Mukundan L., Odegaard J.I., Zhang L., Smith K.L., Morel C.R., Wagner R.A., Greaves D.R., Murray P.J., Chawla A. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab. 2006;4:13–24. doi: 10.1016/j.cmet.2006.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2006.05.011</ArticleId>
            <ArticleId IdType="pmc">PMC1904486</ArticleId>
            <ArticleId IdType="pubmed">16814729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S.C.-C., Everts B., Ivanova Y., O′Sullivan D., Nascimento M., Smith A.M., Beatty W., Love-Gregory L., Lam W.Y., O’Neill C.M., et al.  Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat. Immunol. 2014;15:846–855. doi: 10.1038/ni.2956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2956</ArticleId>
            <ArticleId IdType="pmc">PMC4139419</ArticleId>
            <ArticleId IdType="pubmed">25086775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan D., Yang Q., Shi M., Zhong L., Wu C., Meng T., Yin H., Zhou J. Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway. Eur. J. Immunol. 2013;43:2943–2955. doi: 10.1002/eji.201343472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201343472</ArticleId>
            <ArticleId IdType="pubmed">23897117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu H., Han Y., Sillke Y.R., Deng H., Siddiqui S., Treese C., Schmidt F., Friedrich M., Keye J., Wan J., et al.  Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages. EMBO Mol. Med. 2019;11:e10698. doi: 10.15252/emmm.201910698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201910698</ArticleId>
            <ArticleId IdType="pmc">PMC6835560</ArticleId>
            <ArticleId IdType="pubmed">31602788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su P., Wang Q., Bi E., Ma X., Liu L., Yang M., Qian J., Yi Q. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res. 2020;80:1438–1450. doi: 10.1158/0008-5472.CAN-19-2994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-19-2994</ArticleId>
            <ArticleId IdType="pmc">PMC7127942</ArticleId>
            <ArticleId IdType="pubmed">32015091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiang W., Shi R., Kang X., Zhang X., Chen P., Zhang L., Hou A., Wang R., Zhao Y., Zhao K., et al.  Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression. Nat. Commun. 2018;9:2574. doi: 10.1038/s41467-018-04999-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-04999-8</ArticleId>
            <ArticleId IdType="pmc">PMC6030061</ArticleId>
            <ArticleId IdType="pubmed">29968710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hossain F., Al-Khami A.A., Wyczechowska D., Hernandez C., Zheng L., Reiss K., Del Valle L., Trillo-Tinoco J., Maj T., Zou W., et al.  Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol. Res. 2015;3:1236–1247. doi: 10.1158/2326-6066.CIR-15-0036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0036</ArticleId>
            <ArticleId IdType="pmc">PMC4636942</ArticleId>
            <ArticleId IdType="pubmed">26025381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Divakaruni A.S., Hsieh W.Y., Minarrieta L., Duong T.N., Kim K.K., Desousa B.R., Andreyev A.Y., Bowman C.E., Caradonna K., Dranka B.P., et al.  Etomoxir inhibits macrophage polarization by disrupting CoA homeostasis. Cell Metab. 2018;28:490–503. doi: 10.1016/j.cmet.2018.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2018.06.001</ArticleId>
            <ArticleId IdType="pmc">PMC6125190</ArticleId>
            <ArticleId IdType="pubmed">30043752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veglia F., Tyurin V., Blasi M., De Leo A., Kossenkov A.V., Donthireddy L., To T.K.J., Schug Z., Basu S., Wang F., et al.  Fatty acid transport protein 2 reprograms neutrophils in cancer. Nat. Cell Biol. 2019;569:73–78. doi: 10.1038/s41586-019-1118-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1118-2</ArticleId>
            <ArticleId IdType="pmc">PMC6557120</ArticleId>
            <ArticleId IdType="pubmed">30996346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prima V., Kaliberova L.N., Kaliberov S., Curiel D.T., Kusmartsev S. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc. Natl. Acad. Sci. USA. 2017;114:1117–1122. doi: 10.1073/pnas.1612920114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1612920114</ArticleId>
            <ArticleId IdType="pmc">PMC5293015</ArticleId>
            <ArticleId IdType="pubmed">28096371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goossens P., Rodriguez-Vita J., Etzerodt A., Masse M., Rastoin O., Gouirand V., Ulas T., Papantonopoulou O., Van Eck M., Auphan-Anezin N., et al.  Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 2019;29:1376–1389.e4. doi: 10.1016/j.cmet.2019.02.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2019.02.016</ArticleId>
            <ArticleId IdType="pubmed">30930171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta A., Gorelik E., Prasad S.J., Ronchese F., Lukashev D., Wong M.K.K., Huang X., Caldwell S., Liu K., Smith P., et al.  A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. USA. 2006;103:13132–13137. doi: 10.1073/pnas.0605251103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0605251103</ArticleId>
            <ArticleId IdType="pmc">PMC1559765</ArticleId>
            <ArticleId IdType="pubmed">16916931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin D., Fan J., Wang L., Thompson L.F., Liu A., Daniel B.J., Shin T., Curiel T.J., Zhang B. CD73 on tumor cells impairs antitumor T-cell responses: A novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70:2245–2255. doi: 10.1158/0008-5472.CAN-09-3109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-3109</ArticleId>
            <ArticleId IdType="pmc">PMC2883609</ArticleId>
            <ArticleId IdType="pubmed">20179192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cekic C., Day Y.-J., Sag D., Linden J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res. 2014;74:7250–7259. doi: 10.1158/0008-5472.CAN-13-3583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-3583</ArticleId>
            <ArticleId IdType="pmc">PMC4459782</ArticleId>
            <ArticleId IdType="pubmed">25377469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Barrio I.M., Penski C., Schlahsa L., Stein R.G., Diessner J., Wöckel A., Dietl J., Lutz M.B., Mittelbronn M., Wischhusen J., et al.  Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages—A self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape. J. Immunother. Cancer. 2016;4:49. doi: 10.1186/s40425-016-0154-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-016-0154-9</ArticleId>
            <ArticleId IdType="pmc">PMC4986205</ArticleId>
            <ArticleId IdType="pubmed">27532024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Wang Y., Chu Y., Li Z., Yu X., Huang Z., Xu J., Zheng L. Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma. J. Hepatol. 2021;74:627–637. doi: 10.1016/j.jhep.2020.10.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2020.10.021</ArticleId>
            <ArticleId IdType="pubmed">33137360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bugter J.M., Fenderico N., Maurice M.M. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat. Rev. Cancer. 2021;21:5–21. doi: 10.1038/s41568-020-00307-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-020-00307-z</ArticleId>
            <ArticleId IdType="pubmed">33097916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cosin-Roger J., Ortiz-Masià M.D., Barrachina M.D. Macrophages as an emerging source of Wnt ligands: Relevance in mucosal integrity. Front. Immunol. 2019;10:2297. doi: 10.3389/fimmu.2019.02297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.02297</ArticleId>
            <ArticleId IdType="pmc">PMC6769121</ArticleId>
            <ArticleId IdType="pubmed">31608072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y., Ye Y.C., Chen Y., Zhao J.L., Gao C.C., Han H., Liu W.C., Qin H.Y. Crosstalk between hepatic tumor cells and macrophages via Wnt/beta-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors. Cell Death Dis. 2018;9:793. doi: 10.1038/s41419-018-0818-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0818-0</ArticleId>
            <ArticleId IdType="pmc">PMC6052107</ArticleId>
            <ArticleId IdType="pubmed">30022048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian X., Wu Y., Yang Y., Wang J., Niu M., Gao S., Qin T., Bao D. Long noncoding RNA LINC00662 promotes M2 macrophage polarization and hepatocellular carcinoma progression via activating Wnt/beta-catenin signaling. Mol. Oncol. 2020;14:462–483. doi: 10.1002/1878-0261.12606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12606</ArticleId>
            <ArticleId IdType="pmc">PMC6998656</ArticleId>
            <ArticleId IdType="pubmed">31785055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douglass S.M., Fane M.E., Sanseviero E., Ecker B.L., Kugel C.H., III, Behera R., Kumar V., Tcyganov E.N., Yin X., Liu Q., et al.  Myeloid-derived suppressor cells are a major source of Wnt5A in the melanoma microenvironment and depend on Wnt5A for full suppressive activity. Cancer Res. 2021;81:658–670. doi: 10.1158/0008-5472.CAN-20-1238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-20-1238</ArticleId>
            <ArticleId IdType="pmc">PMC8330365</ArticleId>
            <ArticleId IdType="pubmed">33262126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeVito N.C., Sturdivant M., Thievanthiran B., Xiao C., Plebanek M.P., Salama A.K., Beasley G.M., Holtzhausen A., Novotny-Diermayr V., Strickler J.H., et al.  Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Rep. 2021;35:109071. doi: 10.1016/j.celrep.2021.109071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2021.109071</ArticleId>
            <ArticleId IdType="pmc">PMC8148423</ArticleId>
            <ArticleId IdType="pubmed">33951424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahchan N.S., Mujal A.M., Pollack J.L., Binnewies M., Sriram V., Reyno L., Krummel M.F. Tuning the tumor myeloid microenvironment to fight cancer. Front. Immunol. 2019;10:1611. doi: 10.3389/fimmu.2019.01611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01611</ArticleId>
            <ArticleId IdType="pmc">PMC6673698</ArticleId>
            <ArticleId IdType="pubmed">31402908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Yrigoyen M., Cassetta L., Pollard J.W. Macrophage targeting in cancer. Ann. N. Y. Acad. Sci. 2021;1499:18–41. doi: 10.1111/nyas.14377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.14377</ArticleId>
            <ArticleId IdType="pubmed">32445205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butowski N., Colman H., De Groot J.F., Omuro A.M., Nayak L., Wen P.Y., Cloughesy T.F., Marimuthu A., Haidar S., Perry A., et al.  Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation early phase clinical trials consortium phase II study. Neuro Oncol. 2015;18:557–564. doi: 10.1093/neuonc/nov245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov245</ArticleId>
            <ArticleId IdType="pmc">PMC4799682</ArticleId>
            <ArticleId IdType="pubmed">26449250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmel S., Campone M., Loirat D., López R.L., Beck J.T., De Laurentiis M., Im S.-A., Kim S.-B., Kwong A., Steger G.G., et al.  A randomized phase II study of anti-CSF-1 monoclonal antibody lacnotuzumab (MCS110) combined with gemcitabine and carboplatin in advanced triple negative breast cancer. Clin. Cancer Res. 2021 doi: 10.1158/1078-0432.CCR-20-3955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-20-3955</ArticleId>
            <ArticleId IdType="pubmed">34615719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar V., Donthireddy L., Marvel D., Condamine T., Wang F., Lavilla-Alonso S., Hashimoto A., Vonteddu P., Behera R., Goins M.A., et al.  Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell. 2017;32:654–668. doi: 10.1016/j.ccell.2017.10.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2017.10.005</ArticleId>
            <ArticleId IdType="pmc">PMC5827952</ArticleId>
            <ArticleId IdType="pubmed">29136508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papadopoulos K.P., Gluck L., Martin L.P., Olszanski A., Tolcher A.W., Ngarmchamnanrith G., Rasmussen E., Amore B.M., Nagorsen D., Hill J.S., et al.  First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors. Clin. Cancer Res. 2017;23:5703–5710. doi: 10.1158/1078-0432.CCR-16-3261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-3261</ArticleId>
            <ArticleId IdType="pubmed">28655795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller A.J., Manfredi M.G., Zakharia Y., Prendergast G.C. Inhibiting IDO pathways to treat cancer: Lessons from the ECHO-301 trial and beyond. Semin. Immunopathol. 2019;41:41–48. doi: 10.1007/s00281-018-0702-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-018-0702-0</ArticleId>
            <ArticleId IdType="pubmed">30203227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leone R.D., Emens L.A. Targeting adenosine for cancer immunotherapy. J. Immunother. Cancer. 2018;6:57. doi: 10.1186/s40425-018-0360-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0360-8</ArticleId>
            <ArticleId IdType="pmc">PMC6006764</ArticleId>
            <ArticleId IdType="pubmed">29914571</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
